Neural Therapeutics Inc

Psyence Group Inc. is a life science biotechnology company based in Toronto, Ontario, focused on developing innovative, safe, and effective psychedelic and nature-centered solutions for mental health, particularly in the context of palliative care. The company specializes in natural psilocybin products and medicinal formulations aimed at treating anxiety, depression, and associated ailments within clinical environments. As one of the first federally licensed and ISO 22000 certified facilities for psilocybin cultivation and production, Psyence Group operates under the NASDAQ-listed entity Psyence Biomedical Ltd. The company's team comprises experts in neurology and pharmaceutical product commercialization, alongside a global executive team experienced in capital markets and sustainable growth. Generated from the website

Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America Inc., is committed to advancing health and well-being through innovative pharmaceutical solutions. The company places great emphasis on the ethical collection and management of personal information, ensuring compliance with Canadian privacy laws. With a focus on patient support programs and a strong reliance on technology for improved service offerings, Mitsubishi Tanabe Pharma Canada utilizes various tools to enhance user experience on its platforms. Their data practices reflect a commitment to transparency and user consent in all interactions. Generated from the website

Pharmadrug Inc, based in Toronto, ON, specializes in the clinical development of natural-based medicines and the creation of bio-synthetic formulations for existing drugs. Their focus lies in addressing unmet needs in oncology and infectious diseases through the research, development, and commercialization of innovative treatments. The company is structured around two core divisions: Biotechnology and Synthetic Formulation. The Biotechnology division is dedicated to harnessing the potential of natural compounds, while the Synthetic Formulation division focuses on developing advanced formulations of established medications, particularly in relation to evolving drug policies. Pharmadrug Inc's commitment to advancing healthcare is evident through their emphasis on pioneering approaches to medical treatments and their dedication to improving patient outcomes in critical therapeutic areas. Generated from the website content